158 related articles for article (PubMed ID: 38751033)
1. BRAF-Mutated Melanoma Journey in Latin America: Expert Recommendations From Diagnosis to Treatment.
Bravo-Garzón MA; Bornstein-Quevedo L; Camargo VP; Sanku G; Jansen AM; Macedo MP; Rico-Restrepo M; Chacón M
Cancer Control; 2024; 31():10732748241251572. PubMed ID: 38751033
[TBL] [Abstract][Full Text] [Related]
2. BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting.
Scolyer RA; Atkinson V; Gyorki DE; Lambie D; O'Toole S; Saw RPM; Amanuel B; Angel CM; Button-Sloan AE; Carlino MS; Ch'ng S; Colebatch AJ; Daneshvar D; Pires da Silva I; Dawson T; Ferguson PM; Foster-Smith E; Fox SB; Gill AJ; Gupta R; Henderson MA; Hong AM; Howle JR; Jackett LA; James C; Lee CS; Lochhead A; Loh D; McArthur GA; McLean CA; Menzies AM; Nieweg OE; O'Brien BH; Pennington TE; Potter AJ; Prakash S; Rawson RV; Read RL; Rtshiladze MA; Shannon KF; Smithers BM; Spillane AJ; Stretch JR; Thompson JF; Tucker P; Varey AHR; Vilain RE; Wood BA; Long GV
Pathology; 2022 Feb; 54(1):6-19. PubMed ID: 34937664
[TBL] [Abstract][Full Text] [Related]
3. Prognosis and Management of BRAF V600E-Mutated Pregnancy-Associated Melanoma.
Ziogas DC; Diamantopoulos P; Benopoulou O; Anastasopoulou A; Bafaloukos D; Stratigos AJ; Kirkwood JM; Gogas H
Oncologist; 2020 Aug; 25(8):e1209-e1220. PubMed ID: 32271498
[TBL] [Abstract][Full Text] [Related]
4. Addressing the unmet needs of patients with BRAF-mutated melanoma in Latin America: Expert perspective.
Salman P; de Melo AC; Rico-Restrepo M; Rodriguez J; Russi A; Schmerling RA; Zambrano A; Cinat G
Front Oncol; 2023; 13():1032300. PubMed ID: 36998456
[TBL] [Abstract][Full Text] [Related]
5. COLUMBUS-AD: phase III study of adjuvant encorafenib + binimetinib in resected stage IIB/IIC BRAF V600-mutated melanoma.
van Akkooi AC; Hauschild A; Long GV; Mandala M; Kicinski M; Govaerts AS; Klauck I; Ouali M; Lorigan PC; Eggermont AM
Future Oncol; 2023 Sep; 19(30):2017-2027. PubMed ID: 37665297
[TBL] [Abstract][Full Text] [Related]
6. BRAF Testing in Melanoma and Colorectal Cancer in Latin America: Challenges and Opportunities.
Peixoto RD; Chakhtoura JJA; Aguilar-Ponce JL; Garcia-Rivello H; Jansen AM; Parra Medina R; Ramos-Esquivel A; Stefani SD
Cureus; 2022 Nov; 14(11):e31972. PubMed ID: 36589179
[TBL] [Abstract][Full Text] [Related]
7. Pathologist initiated reflex BRAF mutation testing in metastatic melanoma: experience at a specialist melanoma treatment centre.
Potter AJ; Colebatch AJ; Rawson RV; Ferguson PM; Cooper WA; Gupta R; O'Toole S; Saw RPM; Ch'ng S; Menzies AM; Long GV; Scolyer RA
Pathology; 2022 Aug; 54(5):526-532. PubMed ID: 35249747
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of monitoring circulating tumor cells as a therapeutic biomarker in melanoma with BRAF mutation.
Kiniwa Y; Nakamura K; Mikoshiba A; Ashida A; Akiyama Y; Morimoto A; Okuyama R
BMC Cancer; 2021 Mar; 21(1):287. PubMed ID: 33731038
[TBL] [Abstract][Full Text] [Related]
9. BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy.
Barbour AP; Tang YH; Armour N; Dutton-Regester K; Krause L; Loffler KA; Lambie D; Burmeister B; Thomas J; Smithers BM; Hayward NK
Eur J Cancer; 2014 Oct; 50(15):2668-76. PubMed ID: 25070294
[TBL] [Abstract][Full Text] [Related]
10. Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine.
Cheng L; Lopez-Beltran A; Massari F; MacLennan GT; Montironi R
Mod Pathol; 2018 Jan; 31(1):24-38. PubMed ID: 29148538
[TBL] [Abstract][Full Text] [Related]
11. BRAF mutation testing algorithm for vemurafenib treatment in melanoma: recommendations from an expert panel.
Gonzalez D; Fearfield L; Nathan P; Tanière P; Wallace A; Brown E; Harwood C; Marsden J; Whittaker S
Br J Dermatol; 2013 Apr; 168(4):700-7. PubMed ID: 23360189
[TBL] [Abstract][Full Text] [Related]
12. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF
Schadendorf D; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Lesimple T; Plummer R; Schachter J; Dasgupta K; Manson S; Koruth R; Mookerjee B; Kefford R; Dummer R; Kirkwood JM; Long GV
Lancet Oncol; 2019 May; 20(5):701-710. PubMed ID: 30928620
[TBL] [Abstract][Full Text] [Related]
13. Plasma proteome alterations by MAPK inhibitors in BRAF
Babačić H; Eriksson H; Pernemalm M
Neoplasia; 2021 Aug; 23(8):783-791. PubMed ID: 34246984
[TBL] [Abstract][Full Text] [Related]
14. Impact of Reflex Testing for BRAF Mutational Status in Advanced Melanoma.
Tsang M; Petkiewicz S
Arch Pathol Lab Med; 2022 Dec; 146(12):1535-1539. PubMed ID: 35344989
[TBL] [Abstract][Full Text] [Related]
15. Comparative analysis of adjuvant therapy for stage III BRAF-mut melanoma: A real-world retrospective study from single center in China.
Zhong J; Sun W; Hu T; Wang C; Yan W; Luo Z; Liu X; Xu Y; Chen Y
Cancer Med; 2023 May; 12(10):11475-11482. PubMed ID: 37016119
[TBL] [Abstract][Full Text] [Related]
16. Patterns of treatment and BRAF testing with immune checkpoint inhibitors and targeted therapy in patients with metastatic melanoma presumed to be BRAF positive.
Ghate S; Ionescu-Ittu R; Burne R; Ndife B; Laliberté F; Nakasato A; Duh MS
Melanoma Res; 2019 Jun; 29(3):301-310. PubMed ID: 30247203
[TBL] [Abstract][Full Text] [Related]
17. Which adjuvant treatment for patients with BRAF
Funck-Brentano E; Malissen N; Roger A; Lebbé C; Deilhes F; Frénard C; Dréno B; Meyer N; Grob JJ; Tétu P; Saiag P
Ann Dermatol Venereol; 2021 Sep; 148(3):145-155. PubMed ID: 33579557
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological features and clinical outcomes associated with TP53 and BRAF
Kim DW; Haydu LE; Joon AY; Bassett RL; Siroy AE; Tetzlaff MT; Routbort MJ; Amaria RN; Wargo JA; McQuade JL; Kemnade J; Hwu P; Woodman SE; Roszik J; Kim KB; Gershenwald JE; Lazar AJ; Davies MA
Cancer; 2017 Apr; 123(8):1372-1381. PubMed ID: 27911979
[TBL] [Abstract][Full Text] [Related]
19. BRAF V600 mutation detection in melanoma: a comparison of two laboratory testing methods.
O'Brien O; Lyons T; Murphy S; Feeley L; Power D; Heffron CCBB
J Clin Pathol; 2017 Nov; 70(11):935-940. PubMed ID: 28424234
[TBL] [Abstract][Full Text] [Related]
20. Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testing.
Boursault L; Haddad V; Vergier B; Cappellen D; Verdon S; Bellocq JP; Jouary T; Merlio JP
PLoS One; 2013; 8(8):e70826. PubMed ID: 23976959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
